Amylin Pharmaceuticals (AMLN) Reports Q1 Loss of 24c, Misses by 1c
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
EPS Growth %: +4.2%
Financial Fact:
Operating loss: -54.33M
Today's EPS Names:
CEDU, CHC, CIDM, More
EPS Growth %: +4.2%
Financial Fact:
Operating loss: -54.33M
Today's EPS Names:
CEDU, CHC, CIDM, More
Trade AMLN Now!
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q1 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $152.7 million versus the consensus estimate of $156.73 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jabil Circuit (JBL) Tops Q3 EPS by 2c; Issues Light Q4 Outlook; Will Realign Global Ops
- Korn/Ferry Int'l (KFY) Tops Q4 EPS by 1c, Offers Q1 Guidance
- Micron Technology, Inc. (MU) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, Hot Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
